Academic Journal
Προβολή σε EDS

Serum TGF-β1 and CD14 Predicts Response to Anti-TNF-α Therapy in IBD

Λεπτομέρειες βιβλιογραφικής εγγραφής
Τίτλος: Serum TGF-β1 and CD14 Predicts Response to Anti-TNF-α Therapy in IBD
Συγγραφείς: Coufal, Stepan, Kverka, Miloslav, Kreisinger, Jakub, Thon, Tomas, Rob, Filip, Kolar, Martin, Reiss, Zuzana, Schierova, Dagmar, Kostovcikova, Klara, Roubalova, Radka, Bajer, Lukas, Jackova, Zuzana, Mihula, Martin, Drastich, Pavel, Tresnak Hercogova, Jana, Novakova, Michaela, Vasatko, Martin, Lukas, Milan, Tlaskalova-Hogenova, Helena, Jiraskova Zakostelska, Zuzana
Συνεισφορές: Fang, Weirong, Ministerstvo Zdravotnictví Ceské Republiky, Institute of Microbiology, Chinese Academy of Sciences, Czech Academy of Sciences
Πηγή: Journal of Immunology Research ; volume 2023, page 1-16 ; ISSN 2314-7156 2314-8861
Στοιχεία εκδότη: Wiley
Έτος έκδοσης: 2023
Συλλογή: Wiley Online Library (Open Access Articles via Crossref)
Περιγραφή: Background. Tumor necrosis factor-alpha (TNF-α) agonists revolutionized therapeutic algorithms in inflammatory bowel disease (IBD) management. However, approximately every third IBD patient does not respond to this therapy in the long term, which delays efficient control of the intestinal inflammation. Methods. We analyzed the power of serum biomarkers to predict the failure of anti-TNF-α. We collected serum of 38 IBD patients at therapy prescription and 38 weeks later and analyzed them with relation to therapy response (no-, partial-, and full response). We used enzyme-linked immunosorbent assay to quantify 16 biomarkers related to gut barrier (intestinal fatty acid-binding protein, liver fatty acid-binding protein, trefoil factor 3, and interleukin (IL)-33), microbial translocation, immune system regulation (TNF-α, CD14, lipopolysaccharide-binding protein, mannan-binding lectin, IL-18, transforming growth factor-β1 (TGF-β1), osteoprotegerin (OPG), insulin-like growth factor 2 (IGF-2), endocrine-gland-derived vascular endothelial growth factor), and matrix metalloproteinase system (MMP-9, MMP-14, and tissue inhibitors of metalloproteinase-1). Results. We found that future full-responders have different biomarker profiles than non-responders, while partial-responders cannot be distinguished from either group. When future non-responders were compared to responders, their baseline contained significantly more TGF-β1, less CD14, and increased level of MMP-9, and concentration of these factors could predict non-responders with high accuracy (AUC = 0.938). Interestingly, during the 38 weeks, levels of MMP-9 decreased in all patients, irrespective of the outcome, while OPG, IGF-2, and TGF-β1 were higher in non-responders compared to full-responders both at the beginning and the end of the treatment. Conclusions. The TGF-β1 and CD14 can distinguish non-responders from responders. The changes in biomarker dynamics during the therapy suggest that growth factors (such as OPG, IGF-2, and TGF-β) are not markedly influenced ...
Τύπος εγγράφου: article in journal/newspaper
Γλώσσα: English
DOI: 10.1155/2023/1535484
Διαθεσιμότητα: https://doi.org/10.1155/2023/1535484
http://downloads.hindawi.com/journals/jir/2023/1535484.pdf
http://downloads.hindawi.com/journals/jir/2023/1535484.xml
Rights: https://creativecommons.org/licenses/by/4.0/
Αριθμός Καταχώρησης: edsbas.F6865907
Βάση Δεδομένων: BASE
FullText Text:
  Availability: 0
CustomLinks:
  – Url: https://doi.org/10.1155/2023/1535484#
    Name: EDS - BASE (ns324271)
    Category: fullText
    Text: View record from BASE
Header DbId: edsbas
DbLabel: BASE
An: edsbas.F6865907
RelevancyScore: 929
AccessLevel: 3
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 929.480346679688
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Serum TGF-β1 and CD14 Predicts Response to Anti-TNF-α Therapy in IBD
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22Coufal%2C+Stepan%22">Coufal, Stepan</searchLink><br /><searchLink fieldCode="AR" term="%22Kverka%2C+Miloslav%22">Kverka, Miloslav</searchLink><br /><searchLink fieldCode="AR" term="%22Kreisinger%2C+Jakub%22">Kreisinger, Jakub</searchLink><br /><searchLink fieldCode="AR" term="%22Thon%2C+Tomas%22">Thon, Tomas</searchLink><br /><searchLink fieldCode="AR" term="%22Rob%2C+Filip%22">Rob, Filip</searchLink><br /><searchLink fieldCode="AR" term="%22Kolar%2C+Martin%22">Kolar, Martin</searchLink><br /><searchLink fieldCode="AR" term="%22Reiss%2C+Zuzana%22">Reiss, Zuzana</searchLink><br /><searchLink fieldCode="AR" term="%22Schierova%2C+Dagmar%22">Schierova, Dagmar</searchLink><br /><searchLink fieldCode="AR" term="%22Kostovcikova%2C+Klara%22">Kostovcikova, Klara</searchLink><br /><searchLink fieldCode="AR" term="%22Roubalova%2C+Radka%22">Roubalova, Radka</searchLink><br /><searchLink fieldCode="AR" term="%22Bajer%2C+Lukas%22">Bajer, Lukas</searchLink><br /><searchLink fieldCode="AR" term="%22Jackova%2C+Zuzana%22">Jackova, Zuzana</searchLink><br /><searchLink fieldCode="AR" term="%22Mihula%2C+Martin%22">Mihula, Martin</searchLink><br /><searchLink fieldCode="AR" term="%22Drastich%2C+Pavel%22">Drastich, Pavel</searchLink><br /><searchLink fieldCode="AR" term="%22Tresnak+Hercogova%2C+Jana%22">Tresnak Hercogova, Jana</searchLink><br /><searchLink fieldCode="AR" term="%22Novakova%2C+Michaela%22">Novakova, Michaela</searchLink><br /><searchLink fieldCode="AR" term="%22Vasatko%2C+Martin%22">Vasatko, Martin</searchLink><br /><searchLink fieldCode="AR" term="%22Lukas%2C+Milan%22">Lukas, Milan</searchLink><br /><searchLink fieldCode="AR" term="%22Tlaskalova-Hogenova%2C+Helena%22">Tlaskalova-Hogenova, Helena</searchLink><br /><searchLink fieldCode="AR" term="%22Jiraskova+Zakostelska%2C+Zuzana%22">Jiraskova Zakostelska, Zuzana</searchLink>
– Name: Author
  Label: Contributors
  Group: Au
  Data: Fang, Weirong<br />Ministerstvo Zdravotnictví Ceské Republiky<br />Institute of Microbiology, Chinese Academy of Sciences<br />Czech Academy of Sciences
– Name: TitleSource
  Label: Source
  Group: Src
  Data: Journal of Immunology Research ; volume 2023, page 1-16 ; ISSN 2314-7156 2314-8861
– Name: Publisher
  Label: Publisher Information
  Group: PubInfo
  Data: Wiley
– Name: DatePubCY
  Label: Publication Year
  Group: Date
  Data: 2023
– Name: Subset
  Label: Collection
  Group: HoldingsInfo
  Data: Wiley Online Library (Open Access Articles via Crossref)
– Name: Abstract
  Label: Description
  Group: Ab
  Data: Background. Tumor necrosis factor-alpha (TNF-α) agonists revolutionized therapeutic algorithms in inflammatory bowel disease (IBD) management. However, approximately every third IBD patient does not respond to this therapy in the long term, which delays efficient control of the intestinal inflammation. Methods. We analyzed the power of serum biomarkers to predict the failure of anti-TNF-α. We collected serum of 38 IBD patients at therapy prescription and 38 weeks later and analyzed them with relation to therapy response (no-, partial-, and full response). We used enzyme-linked immunosorbent assay to quantify 16 biomarkers related to gut barrier (intestinal fatty acid-binding protein, liver fatty acid-binding protein, trefoil factor 3, and interleukin (IL)-33), microbial translocation, immune system regulation (TNF-α, CD14, lipopolysaccharide-binding protein, mannan-binding lectin, IL-18, transforming growth factor-β1 (TGF-β1), osteoprotegerin (OPG), insulin-like growth factor 2 (IGF-2), endocrine-gland-derived vascular endothelial growth factor), and matrix metalloproteinase system (MMP-9, MMP-14, and tissue inhibitors of metalloproteinase-1). Results. We found that future full-responders have different biomarker profiles than non-responders, while partial-responders cannot be distinguished from either group. When future non-responders were compared to responders, their baseline contained significantly more TGF-β1, less CD14, and increased level of MMP-9, and concentration of these factors could predict non-responders with high accuracy (AUC = 0.938). Interestingly, during the 38 weeks, levels of MMP-9 decreased in all patients, irrespective of the outcome, while OPG, IGF-2, and TGF-β1 were higher in non-responders compared to full-responders both at the beginning and the end of the treatment. Conclusions. The TGF-β1 and CD14 can distinguish non-responders from responders. The changes in biomarker dynamics during the therapy suggest that growth factors (such as OPG, IGF-2, and TGF-β) are not markedly influenced ...
– Name: TypeDocument
  Label: Document Type
  Group: TypDoc
  Data: article in journal/newspaper
– Name: Language
  Label: Language
  Group: Lang
  Data: English
– Name: DOI
  Label: DOI
  Group: ID
  Data: 10.1155/2023/1535484
– Name: URL
  Label: Availability
  Group: URL
  Data: https://doi.org/10.1155/2023/1535484<br />http://downloads.hindawi.com/journals/jir/2023/1535484.pdf<br />http://downloads.hindawi.com/journals/jir/2023/1535484.xml
– Name: Copyright
  Label: Rights
  Group: Cpyrght
  Data: https://creativecommons.org/licenses/by/4.0/
– Name: AN
  Label: Accession Number
  Group: ID
  Data: edsbas.F6865907
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=edsbas&AN=edsbas.F6865907
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1155/2023/1535484
    Languages:
      – Text: English
    Titles:
      – TitleFull: Serum TGF-β1 and CD14 Predicts Response to Anti-TNF-α Therapy in IBD
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Coufal, Stepan
      – PersonEntity:
          Name:
            NameFull: Kverka, Miloslav
      – PersonEntity:
          Name:
            NameFull: Kreisinger, Jakub
      – PersonEntity:
          Name:
            NameFull: Thon, Tomas
      – PersonEntity:
          Name:
            NameFull: Rob, Filip
      – PersonEntity:
          Name:
            NameFull: Kolar, Martin
      – PersonEntity:
          Name:
            NameFull: Reiss, Zuzana
      – PersonEntity:
          Name:
            NameFull: Schierova, Dagmar
      – PersonEntity:
          Name:
            NameFull: Kostovcikova, Klara
      – PersonEntity:
          Name:
            NameFull: Roubalova, Radka
      – PersonEntity:
          Name:
            NameFull: Bajer, Lukas
      – PersonEntity:
          Name:
            NameFull: Jackova, Zuzana
      – PersonEntity:
          Name:
            NameFull: Mihula, Martin
      – PersonEntity:
          Name:
            NameFull: Drastich, Pavel
      – PersonEntity:
          Name:
            NameFull: Tresnak Hercogova, Jana
      – PersonEntity:
          Name:
            NameFull: Novakova, Michaela
      – PersonEntity:
          Name:
            NameFull: Vasatko, Martin
      – PersonEntity:
          Name:
            NameFull: Lukas, Milan
      – PersonEntity:
          Name:
            NameFull: Tlaskalova-Hogenova, Helena
      – PersonEntity:
          Name:
            NameFull: Jiraskova Zakostelska, Zuzana
      – PersonEntity:
          Name:
            NameFull: Fang, Weirong
      – PersonEntity:
          Name:
            NameFull: Ministerstvo Zdravotnictví Ceské Republiky
      – PersonEntity:
          Name:
            NameFull: Institute of Microbiology, Chinese Academy of Sciences
      – PersonEntity:
          Name:
            NameFull: Czech Academy of Sciences
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 01
              Type: published
              Y: 2023
          Identifiers:
            – Type: issn-locals
              Value: edsbas
            – Type: issn-locals
              Value: edsbas.oa
          Titles:
            – TitleFull: Journal of Immunology Research ; volume 2023, page 1-16 ; ISSN 2314-7156 2314-8861
              Type: main
ResultId 1